Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on December 18, 2014, regarding events occurring on December 17, 2014. The filing primarily addresses corporate governance changes involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors:
- Appointee: Kathy Ordoñez, age 64.
- Role: Class II Director, effective immediately.
- Background: Former Senior Vice President of Diagnostic Solutions at Quest Diagnostics, Inc.; former CEO of Celera Corporation; former President and CEO of Roche Molecular Systems.
Compensation and Governance Details
As a non-employee director, Ms. Ordoñez's compensation package includes:
- Annual Retainer: $35,000.
- Equity Grant: Automatic grant of a stock option to purchase 35,000 shares of common stock on the date of appointment.
The Company issued a press release on December 18, 2014, to disclose this appointment under Regulation FD.
Investor Verification Checklist
- Verify the effective date of Ms. Ordoñez's board appointment (December 17, 2014).
- Confirm the specific terms of the stock option grant (35,000 shares) and annual retainer ($35,000).
- Review the attached press release (Exhibit 99.1) for additional biographical details or strategic rationale not included in the 8-K text.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.